GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

BACKGROUND: There is lack of evidence about systemic treatment of pseudomyxoma peritonei (PMP) relapsing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. There is also lack of biomarkers able to predict outcomes beyond known clinical and pathological prognostic features. ME...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Transl Med
Asıl Yazarlar: Pietrantonio, Filippo, Berenato, Rosa, Maggi, Claudia, Caporale, Marta, Milione, Massimo, Perrone, Federica, Tamborini, Elena, Baratti, Dario, Kusamura, Shigeki, Mariani, Luigi, Niger, Monica, Mennitto, Alessia, Gloghini, Annunziata, Bossi, Ilaria, Settanni, Giulio, Busico, Adele, Bagnoli, Pietro Francesco, Di Bartolomeo, Maria, Deraco, Marcello, de Braud, Filippo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2016
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4859944/
https://ncbi.nlm.nih.gov/pubmed/27154293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-0877-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller